SCHEMBL25099265

SCHEMBL25099265

CC(C)C(=O)O[C@@H](CC(=O)O)C[N+](C)(C)C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.66
▸ SMN1; SMN2 Q16637 1/20 0.66
▸ CYP1A2 P05177 4/20 0.55
▸ MAPK1 P28482 4/20 0.54
▸ MAPT P10636 4/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ GMNN O75496 3/20 0.54
▸ NPSR1 Q6W5P4 3/20 0.54
▸ TSHR P16473 3/20 0.54
▸ HSP90AA1 P07900 2/20 0.54
▸ BLM P54132 2/20 0.54
▸ NR1H4 Q96RI1 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ GLA P06280 1/20 0.53
▸ PMP22 Q01453 1/20 0.53
▸ HRH1 P35367 1/20 0.47
▸ CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12152164 1.00 LMNA (0.66) LMNASMN1; SMN2CYP1A2MAPK1MAPT
SCHEMBL12137159 1.00 LMNA (0.66) LMNASMN1; SMN2CYP1A2MAPK1MAPT
Bromide SCHEMBL2995962 0.98 LMNA (0.64) LMNASMN1; SMN2CYP1A2MAPK1MAPT
Hydrochloric Acid SCHEMBL8752462 0.98 LMNA (0.69) LMNASMN1; SMN2CYP1A2MAPK1MAPT
SCHEMBL27777262 0.89 LMNA (0.62) LMNASMN1; SMN2CYP1A2MAPK1MAPT
Butyryl-Carnitine SCHEMBL25274079 0.88 CYP1A2 (0.68) LMNASMN1; SMN2CYP1A2MAPK1MAPT
SCHEMBL20530318 0.87 LMNA (0.64) LMNASMN1; SMN2CYP1A2MAPK1MAPT
SCHEMBL20530359 0.87 LMNA (0.64) LMNASMN1; SMN2CYP1A2MAPK1MAPT
SCHEMBL27768779 0.85 LMNA (0.66) LMNASMN1; SMN2CYP1A2MAPK1MAPT
SCHEMBL27925466 0.85 LMNA (0.66) LMNASMN1; SMN2CYP1A2MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037354-B2 Cyclic pantetheine derivatives and uses thereof VECTIVBIO COMET AG (CH) 2024-07-16 — — US disclosed
US-20230072313-A1 CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) 2023-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072313-A1 CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF VNN1, VKORC1, PANK3 LMNA 1802/4885SMN1; SMN2 3480/4885CYP1A2 503/4885
US-12037354-B2 Cyclic pantetheine derivatives and uses thereof VNN1, VKORC1, PANK3 LMNA 1802/4885SMN1; SMN2 3480/4885CYP1A2 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback